CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-02-01 Epub Date: 2024-12-20 DOI:10.1080/14796694.2024.2441649

Takahiro Nakayama, Linghua Xu, Yasuaki Muramatsu

{"title":"CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.","authors":"Takahiro Nakayama, Linghua Xu, Yasuaki Muramatsu","doi":"10.1080/14796694.2024.2441649","DOIUrl":null,"url":null,"abstract":"Background: Though efforts have been made toward standardizing access to quality cancer care in Japan, there are still geographical and institutional disparities in the level of cancer care availability. We investigated the utilization of cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy (CDK4/6i+ET) as first-line (1 L) treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan.Research design and methods: This cross-sectional survey included physicians who had treated ≥3 1 L patients with HR+/HER2- ABC in the past year.Results: Of 41,695 physicians invited, 300 were included in the analysis. The mean percentage share of CDK4/6i+ET and ET monotherapy was 38.3% and 42.2%, respectively. Common challenges facing CDK4/6i+ET prescription were adverse reaction management, prohibitive cost, and a preference for ET monotherapy for treating elderly patients. Key solutions included reducing the burden of adverse reaction management, improving financial support, and preparing educational videos for medical staff.Conclusions: The study concluded that CDK4/6i+ET is not well established as a 1 L option in Japan as of 2022. More effective ways of creating awareness and supportive tools are needed for CDK4/6i+ET to be adopted as standard of care in Japan.Trial registration number: UMIN000050760.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"321-330"},"PeriodicalIF":3.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792832/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2441649","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Though efforts have been made toward standardizing access to quality cancer care in Japan, there are still geographical and institutional disparities in the level of cancer care availability. We investigated the utilization of cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy (CDK4/6i+ET) as first-line (1 L) treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan.

Research design and methods: This cross-sectional survey included physicians who had treated ≥3 1 L patients with HR+/HER2- ABC in the past year.

Results: Of 41,695 physicians invited, 300 were included in the analysis. The mean percentage share of CDK4/6i+ET and ET monotherapy was 38.3% and 42.2%, respectively. Common challenges facing CDK4/6i+ET prescription were adverse reaction management, prohibitive cost, and a preference for ET monotherapy for treating elderly patients. Key solutions included reducing the burden of adverse reaction management, improving financial support, and preparing educational videos for medical staff.

Conclusions: The study concluded that CDK4/6i+ET is not well established as a 1 L option in Japan as of 2022. More effective ways of creating awareness and supportive tools are needed for CDK4/6i+ET to be adopted as standard of care in Japan.

Trial registration number: UMIN000050760.

查看原文本刊更多论文

CDK4/6抑制剂加内分泌治疗晚期乳腺癌：日本一项基于网络的调查结果

背景：虽然在日本已经为标准化获得高质量的癌症治疗做出了努力，但在癌症治疗的可用性水平上仍然存在地理和制度上的差异。我们在日本研究了细胞周期蛋白依赖性激酶4/6抑制剂联合内分泌治疗（CDK4/6i+ET）作为激素受体阳性(HR+)/人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）的一线（1l）治疗。研究设计和方法：这项横断面调查包括在过去一年中治疗≥31 L例HR+/HER2- ABC患者的医生。结果：被邀请的41695名医生中，有300人被纳入分析。CDK4/6i+ET和ET单药治疗的平均百分比分别为38.3%和42.2%。CDK4/6i+ET处方面临的共同挑战是不良反应管理、高昂的成本以及对老年患者ET单药治疗的偏好。关键解决方案包括减轻不良反应管理负担、改善财政支持以及为医务人员制作教育视频。结论：该研究得出结论，截至2022年，CDK4/6i+ET在日本尚未被很好地确定为1 L选择。为了使CDK4/6i+ET成为日本的标准治疗，需要更有效的方法来提高认识和支持性工具。试验注册号：UMIN000050760。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.